Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Nevada Tech Journal.
Press releases published on June 23, 2025
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
GlobeNewswire
·
June 23, 2025
Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies Top-line data expected in the first quarter of 2026 WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: …
NETCLASS TECHNOLOGY INC and Nanyang Institute of Social Sciences Join Forces to Explore New Paths in Smart Education
GlobeNewswire
·
June 23, 2025
SHANGHAI and HONG KONG, June 23, 2025 (GLOBE NEWSWIRE) -- NETCLASS Technology INC (Nasdaq: NTCL; the “Company” or “NetClass”), a leading B2B smart education IT solutions provider with offices in Shanghai, Hong Kong, Singapore and Tokyo, is pleased to …
CorMedix inc. Announces Customer Implementation
GlobeNewswire
·
June 23, 2025
BERKELEY HEIGHTS, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces an update …
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
GlobeNewswire
·
June 23, 2025
Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform, focused on orthopedic diseases OrthoCellix is …
Quid Miner is the latest free cloud mining application, one-click mining Bitcoin (BTC), Dogecoin (DOGE), Litecoin (LTC)
GlobeNewswire
·
June 23, 2025
Lansing, Michigan, June 23, 2025 (GLOBE NEWSWIRE) -- Riding the wave of the global cryptocurrency market, Quid Miner is launching a future-oriented free cloud mining application designed to provide users with an immersive, secure and authentic experience …
Alterity Therapeutics to Provide Corporate Update in Fireside Chat
GlobeNewswire
·
June 23, 2025
MELBOURNE, Australia and SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative …
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
GlobeNewswire
·
June 23, 2025
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved a label …
OXB completes acquisition of remaining stake in US subsidiary
GlobeNewswire
·
June 23, 2025
OXB completes acquisition of remaining stake in US subsidiary Progression to full ownership aligns with global strategy and supports long-term growth in the viral vector manufacturing market Oxford, UK – 23 June 2025: OXB (LSE: OXB) (“the Company”), a …
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study
GlobeNewswire
·
June 23, 2025
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Robust central nervous system (CNS) activity; 41% (7/17) confirmed complete response (CR) and 53% confirmed …
Avalo Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
·
June 23, 2025
WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor …
ATR Launches Free Logistics Program to Introduce Businesses to Cost-Effective, Secure ITAD Solutions in the Gulf Coast Region and Beyond
GlobeNewswire
·
June 23, 2025
PENSACOLA, Fla., June 23, 2025 (GLOBE NEWSWIRE) -- Advanced Technology Recycling (ATR), a national leader in IT asset disposition (ITAD) and R2v3/RIOS certified electronics recycling, is excited to launch a limited-time complimentary logistics program for …
Elevate Your Summer with Canada’s Leading Cannabis Brands and Products by Tilray Brands
GlobeNewswire
·
June 23, 2025
TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, announces its 2025 summer cannabis …
FactSet Reports Results for Third Quarter 2025
GlobeNewswire
·
June 23, 2025
Q3 GAAP revenues of $585.5 million, up 5.9% from Q3 2024. Organic Q3 ASV of $2,296.9 million, up 4.5% year over year. Q3 GAAP operating margin of 33.2%, down approximately 350 bps year over year, and adjusted operating margin of 36.8%, down 270 bps year …
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
GlobeNewswire
·
June 23, 2025
PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days, …
Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program
GlobeNewswire
·
June 23, 2025
Interactions with FDA over the past year have provided clear expectations for the path to submission of the nomlabofusp BLA Written FDA recommendations for safety database include a total of at least 30 participants with continuous exposure for 6 months …
Denovo Biopharma LLC Enters into an Exclusive Out-License Agreement with Chuang Yi Global Asset Management Co., Ltd. for Biomarker-Guided DB104 (liafensine) in Patients with Treatment-Resistant Depression (TRD) in Taiwan
GlobeNewswire
·
June 23, 2025
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative drugs, today announced that it has out-licensed its biomarker-guided DB104 (liafensine) program to one of Taiwan’s …
Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association’s 85th Scientific Sessions
GlobeNewswire
·
June 23, 2025
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the debut of …
Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza
GlobeNewswire
·
June 23, 2025
The study met its primary and all secondary efficacy endpoints for all dose groups Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo CD388 was …
AltruBio Presents New Preclinical Data at FOCIS 2025 Demonstrating ALTB-268’s Efficacy in T Cell-Mediated Inflammatory Models
GlobeNewswire
·
June 23, 2025
ALTB-268 demonstrated therapeutic potential in murine models of colitis and GvHD, supporting its role as an immune checkpoint enhancer in T cell-mediated inflammatory diseases Findings reinforce ALTB-268’s ability to downregulate T cell effector function …
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)
GlobeNewswire
·
June 23, 2025
In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass, outperforming the group given semaglutide alone Icovamenib …